Close this search box.

Myalgic Encephalomyelitis: Unknown Cause. No Cure. New Hope. (ASBMBToday)

By Lily Williams

Lizzie Mooney is 12 years old. She is tall for her age with long blonde hair. She likes to wear Chicago Bears pajama bottoms and a hoodie. She’s funny, making up games and teasing her siblings.

Lizzie excels in reading and math. She spends time crafting and watches science shows with her parents at night. But it’s hard for her to make it downstairs to the TV room. She can’t go to school. In fact, she might only leave her house once a week.

For the past three years, Lizzie has been sick.

Lizzie Mooney has myalgic encephalomyelitis. Her health has decreased over the past three years to the point where she can barely leave her house or even eat meals at the table with her family. LILY WILLIAMS

The government estimates that as many as 1 million to 2.5 million Americans have the same disease as Lizzie: myalgic encephalomyelitis, or ME. Despite these numbers, you probably haven’t heard of ME. What you might have heard of instead is chronic fatigue syndrome, or CFS. This euphemism for ME conjures an image of someone who just doesn’t feel like getting out of bed.

Lizzie Mooney has myalgic encephalomyelitis. Her health has decreased over the past three years to the point where she can barely leave her house or even eat meals at the table with her family. LILY WILLIAMS

For many ME patients, getting out of bed would be the highlight of their week or month. About 25 percent of patients are housebound, in rooms with the blinds drawn and noises muffled. Patients’ bodies are sensitive to all kinds of stimulation; they suffer from gastrointestinal problems, inability to sleep, chronic pain and the disease’s trademarks: cognitive dysfunction and post-exertional malaise, or PEM. Many patients describe PEM as a crash. Something as simple as a short walk can severely worsen a patient’s symptoms, leaving them bedridden, unable to recover, for weeks or months. There’s no telling how long the crash will last. Imagine having to decide between taking a shower and making yourself lunch. It could be your only activity for the week. Patients with ME have reported lower quality-of-life scores than patients with terminal cancer and heart disease.

Yet federal funding for ME research remains at a fraction of what is spent on each of these. In fact, research funding for ME remains less than what the government spends on headaches or hay fever. Multiple sclerosis funding is 12 times the funding for ME, but an estimated 400,000 patients in the U.S. have MS, fewer than half the number who have ME even according to the most conservative estimate.

When Lizzie got sick, her mother, Amy Mooney, took her to their primary care physician, who diagnosed Lizzie with a mononucleosislike illness. Lizzie spent the next four months in bed. Mooney took her to infectious disease doctors, rheumatologists, neurologists and gastroenterologists, but no one could make a diagnosis.

“The most painful moment was when an infectious disease doctor took me into the hallway,” Amy Mooney said. “He said, ‘Congratulations. Her blood work is completely normal. Nothing is wrong with her.’ In the patient room, they were asking Lizzie if we have a healthy family life: Do we have abusive family situations?

Are we going through a divorce?

“The physician at the pediatric hospital wrote a note to the school saying it was safe for her to go to school,” Mooney said. “‘Get her back to school. Kids with cancer go to school.’”

Lizzie hasn’t been to school since she was nine. She works at home with a private tutor when she can.

Lizzie makes her way down the stairs for a morning tutoring session. Immediately after these sessions, and sometimes, halfway through, she retreats to her dark bedroom, where she sometimes shakes in pain for hours. LILY WILLIAMS

For decades, the search for pathogenic underpinnings for ME came up empty, and the disease was attributed to psychological causes. Stigma, skepticism and limited funding have fueled what advocates characterize as a vicious cycle that’s left a big hole in ME research. But advances in our understanding of the gut microbiome, cell-mediated immunity, mitochondrial dysfunction and dozens of other variables may open the door to new approaches to understanding and treating the disease.

While ME’s existence is no longer controversial, within the ME community, federal funding for ME research is. In recent years, the National Institutes of Health has spent between $5 million and $8 million a year on ME research. In 2017, the NIH earmarked $7 million for a first-time ME research collaboration of four centers. But some advocates say the government should be dedicating more than 50 times that amount.

Steps in the right direction?

Among those advocates is journalist Hillary Johnson, who says billions of dollars would be an appropriate figure.

Johnson spent almost a decade during the 1980s and 1990s researching the befuddling lack of interest in ME by government entities such as the Centers for Disease Control and Prevention and the NIH. She compiled her findings into a book, “Osler’s Web.”

In her book, Johnson chronicles the ’80s as a time when the CDC actively buried ME research and funding. She also casts Stephen Straus, a senior investigator in the Laboratory of Clinical Investigation at the NIH’s National Institute of Allergy and Infectious Diseases, or NIAID, from 1991 to 1999, as the chief villain. Straus published a number of studies on ME, some of which psychologized the disease. Straus went on to become the first director of the National Center for Complementary and Alternative Medicine. When he died in 2007, he was warmly remembered by his colleagues and was lauded by the NIH for what was then still called chronic fatigue research.

Professors Maureen Hanson and Andrew Grimson examine a cartridge containing DNA at Cornell University’s high-throughput sequencer, used for ME / CFS research. COURTESY OF LINDSAY FRANCE/CORNELL UNIVERSITY

Joseph Breen is the current chief of the immunoregulation section in the Division of Allergy, Immunology and Transplantation at the NIAID. “Fortunately, perspectives about the disease have changed,” Breen said. “Researchers now have the tools to explore possible etiologies of ME / CFS and future studies should be revealing, especially those with larger cohorts, initiated early after disease onset and with longitudinal follow-up.”

The NIH announcement in September of four grants totaling more than $7 million for fiscal year 2017, and continuing for the next five years, signifies a step in official ME recognition. The new NIH grants will support three collaborative research centers and a data-management coordinating center for ME research. One grant is going to researchers at Cornell University led by principal investigator and American Society for Biochemistry and Molecular Biology member Maureen Hanson. A 2016 study in Hanson’s lab found that ME patients’ microbiomes have significantly lower microbial diversity and a higher incidence of pro-inflammatory species than in healthy controls.

Hanson’s work also branches into fatty acid and lipid metabolism. Her lab produced a 2017 paper on a study that found significant disturbances in numerous fatty acid and amino acid metabolism pathways. Levels of energy-related metabolites, such as ATP and ADP, were significantly lower in ME patients. Acetylcarnosine and taurine, important to muscle tissues, also were less abundant.

Hanson and her colleagues at Cornell will use the new NIH grant to study post-exertional malaise using neuroimaging, metabolomics and single-cell RNA sequencing.

The researchers will take blood samples before and after the study participants ride stationary bicycles on two consecutive days.

To determine why ME patients usually can’t replicate their initial performances, the researchers will search their blood samples for biomarkers.

Hanson’s specific role in the project will be to study extracellular vesicles, which transport materials between cells. In healthy people, exercise induces release of these vesicles, which may mediate the beneficial effects of physical activity.

“This is going to be an important study to carry out — at the time we wrote our proposal, there were no published studies about extracellular vesicles in ME,” Hanson said.

If patients can fall into severe PEM after even basic activities, how could Hanson’s team find ME patients willing to do two days of exercise testing?

Little is known about how ME affects Lizzie’s bodily systems, but the disease prevents her from interacting with her peers or traveling with her family. LILY WILLIAMS

“Even though the exercise will likely induce a relapse, most of the patients don’t report that they never recover, otherwise we would never do it,” Hanson said of the tests. “In fact, some of these patients ask to return to obtain needed disability documentation. It is right now the most objective way for someone to demonstrate their disability. A lot of them have a great deal of trouble convincing insurance companies or the social security agency that they are actually disabled.”

U.S. medical record and insurance billing codes still classify ME as chronic fatigue — as a symptom rather than a disease. Even with a diagnosis, the insurance companies would not cover Lizzie’s prescription medications or supplements, which cost the Mooneys upward of $1,000 each month. One study estimates conservatively that ME patients pay $8,675 per year for treatments, and the direct cost to the U.S. healthcare system for all patients could top $7 billion.

Also under the NIH grant, researchers led by Dikoma Shungu at Weill Cornell Medical College will do one of the first neuroimaging tests on ME patients experiencing PEM.The other two NIH research centers include ateam at Columbia University that will look for microbial agents and evidence for immune responses to microbes and a team at the Jackson Laboratory in Farmington, Connecticut, that will study how the body’s immune system, microbiome and metabolism interact.

The Research Triangle Institute in North Carolina will house the data-management center, bringing data from the three centers into one database for standardization and providing tools for data processing and analytics.

“This is a very important step by the NIH,” Hanson said. “But we need more centers and individual studies relative to the burden of illness and number of people who are ill. The number of research dollars is really inadequate.”

Breen said he hopes that researchers will be encouraged by the NIH’s increased commitment to ME research and will continue to apply for more funds.

“The NIH ME / CFS working group functions as a team and we’re just starting the ME / CFS Collaborative Research Center program,” he said. “In the next five years, we hopefully will grow the community with a network of ME / CFS centers and small investigator-initiated research project grants.”

Millions missing

Rivka Solomon has had ME for 28 years, and she is a vocal advocate for increased research funding. Here she speaks as the host of a screening of “Unrest,” a 2017 documentary about ME.COURTESY OF RIVKA SOLOMON

Rivka Solomon, 55, has had ME for 28 years.

When called for a phone interview, she didn’t answer, even though she had seemed eager to talk during email exchanges to schedule the interview. She called back 25 minutes late.

“Cognitively … I remembered your call, but then I forgot,” she said. “See, this is what happens. On bad days, my brain does not work well. And neither does my body. During a relapse it can take me 45 minutes to get up a set of stairs because I have to rest between each step.”

When Solomon was 21, she and her two roommates all got mononucleosis at the same time. Her friends got better. Solomon stayed sick for a year. Then she went through a seven-year period of what she calls a relative remission before falling ill again. She lives in Massachusetts and works from home as a writer and ME advocate, when she has energy.

Solomon represents most ME patients and advocates when she says that the amount of funding ME receives — even with new grants — is way too low.

Journalist Hillary Johnson compares ME to AIDS, for which funding increased drastically “once they realized it could be transmitted.” Many clinicians and researchers Johnson interviewed for “Osler’s Web” in the ’80s and ’90s believed ME had a contagious, infectious cause. In particular geographic locations around the world, doctors began seeing clusters of patients with crippling fatigue and neurological problems.

Now, HIV/AIDS receives about $3 billion in NIH funding each year for biomedical research on treatment, cure, prevention, and co-morbidities and co-infections. An estimated 1.1 million Americans have HIV. Adequate funding has led to HIV drug therapies that allow patients to lead semi-normal lives. ME is nowhere close to having a drug therapy, and its patients are crippled by bodies that cannot perform even minor tasks.

In 2018, still no cause — infectious or otherwise — has been found, even though thousands of papers have found biological abnormalities in ME patients.

Although new technologies and funding now exist, Solomon believes the real reason ME hasn’t been elucidated is that the federal government has failed to fund disease research in proportion to ME’s high burden of illness. This lack of funding hasn’t incentivized new researchers to study ME and has propagated the idea that ME is psychological, not physical, Solomon says. One highly visible study has helped promote the psychological theory of ME.

The controversial U.K. study, known as the PACE trial, was published in 2011, just seven years ago. The results of the $8 million experiments were similar to ME studies from the 1980s. PACE researchers asserted that ME patients had a false illness belief, making them reticent to exercise or lead a normal, healthy life, perpetuating feelings of illness. Patients could recover from this false belief, researchers said, through graded exercise therapy and cognitive behavioral therapy to help them realize they were not, in fact, ill at all.

An eight-week exercise program worsened Lizzie Mooney to the point that she was bedridden. And Amy Mooney cites another young patient whose goal for her exercise program was to overcome crippling stomach pain and stop using a wheelchair. The exercise made her sicker.

The PACE trial came under fire in 2015. David Tuller, a senior fellow in public health and journalism at the University of California, Berkeley’s School of Public Health, pointed out problems with the study that included author ties to disability insurance companies, a baseline scoring system that rated patients as simultaneously sick enough for the study yet healthy enough to be recovered, and a newsletter of patient testimonials released midway through the study that claimed benefits of the therapy.

“There could be 17 to 20 million of us or more around the world,” Solomon said, “and yet they still think we’re making this up.”

Millions needed

Linda Tannenbaum, CEO and president of Open Medicine Foundation, gives a presentation. Her daughter fell ill in 2006 with sudden-onset ME. Tannenbaum has since raised more than $13 million for research. COURTESY OF LINDA TANNENBAUM

Advocates such as Linda Tannenbaum are concerned that some qualified ME researchers aren’t being funded by the NIH. In 2006, Tannenbaum’s daughter fell ill with sudden-onset ME. Tannenbaum, who lives in Agoura Hills, California, had worked in clinical lab science for over 23 years and had her own medical laboratory, but she’d never heard of ME. “We were told that she had something called chronic fatigue syndrome and there was nothing we could do for her other than pain management,” she said.

Tannenbaum set out to find a cure. By 2012, she had formed Open Medicine Foundation. She has since raised more than $13 million, much of it from the less-than-affluent patient community. An anonymous bitcoin philanthropist from the Pineapple Fund gave $5 million to OMF early in February.

“This disease is real, as emphasized by the caliber of researchers working together on this,” said Tannenbaum, who has helped to gather a global collaborative cohort of ME researchers.

OMF’s 15-member scientific advisory board includes three Nobel laureates and six National Academy of Science members. Hanson, from Cornell, is on the advisory board but her ME research is not funded by OMF.

Stanford University researchers, already funded by OMF for ME work, applied for but did not receive any of the new NIH grants. So the OMF leaders decided to fund another ME / CFS research center at Stanford University, supplying a grant starting at $1.2 million and continuing for as long as OMF can raise enough funds. More than 20 scientists will make up the OMF-funded center at Stanford, along with a growing working group of more than 30 researchers from top U.S. and international universities, who are not funded by OMF.

The Stanford ME center is led by ASBMB member Ronald W. Davis, director of OMF’s scientific advisory board and director of the Stanford Genome Technology Center. Davis’ son is severely ill with ME; he cannot leave his room, eat food or even speak. Davis has studied heavy metals and viruses in ME patients. He has coordinated a large -omics study on severely ill patients, a subgroup never studied before, analyzing genome sequences, proteins, metabolites, small RNA molecules and more. Severely ill patients are those who are homebound or bedbound, such as Davis’ son, who lacks the energy even to look at people. Davis hopes that his current and future research will help establish a large and open database where researchers can put new data to use in concert.

“People think they need to create their own big data and keep it to themselves, but this is expensive,” Davis said. “The rate-limiting step from publishing and getting ME research done is funding. I wish we had a lot more money to give everyone to make this much faster.”

Once two grades above her age in math and reading levels, Lizzie can now complete only 45 minutes of home tutoring per day due to the severity of her illness. She is pictured with her tutor, Judith Meyer. LILY WILLIAMS

The NIH was reluctant to fund his initial ME observational experiments, Davis said. But observation is needed before any hypotheses and future research directions can be established, he said, especially when so little observation has been done on ME. He hopes data he soon will publish will allow specialized researchers to study ME in their own fields, without the need to do costly and lengthy background research beforehand.

Jose Montoya, an ME physician and professor of medicine at Stanford, published a 2017 paper in the Proceedings of the National Academy of Sciences that analyzed an unusually high number of ME patients and controls as compared to typical ME studies: Serum from 192 patients and 392 healthy controls was analyzed for ytokine differences. Immune cells secrete cytokines, or cell-signaling molecules that play a role in inflammation. The signature flu-like symptoms and muscle pain led researchers to believe ME could be an inflammatory disorder.

Montoya and his team found that two cytokines were significantly different in ME patients and healthy controls. TGF-beta, found commonly in the monocytes and macrophages of the immune system as well as intestinal epithelial cells, is viewed as an anti-inflammatory cytokine. TGF-beta was higher in ME patients. Resistin, produced primarily by peripheral blood mononuclear cells, has been shown to increase transcription of pro-inflammatory genes and was lower in severe ME patients but higher in moderate ME patients. In total, Montoya’s study found 17 cytokines, 13 of which are pro-inflammatory, that had an upward linear trend when put into context of ME severity. In other words, these cytokines’ levels were higher in patients who had more severe symptoms. The study also cites resistin and another adipokine, leptin, as cytokines secreted by adipose tissue that could be important. Leptin has been found to correlate with fatigue severity, and levels are higher in females. Adipokines contribute to crosstalk between the central nervous system and adipose tissue and could contribute to neuroinflammation and cognitive dysfunction in ME patients. In mice, leptin has demonstrated a recruitment of neutrophils to the brain during sepsis, prompted by administration of lipopolysaccharide.

The new OMF-funded center at Stanford will have three main projects. One will explore the immunological basis of ME through analysis of T cells, the human immune cells that kill their infected own. ME could affect T-cell replication and behavior. This study also will investigate the way personal variations in human leukocyte antigen genes regulate immunity in ME patients. These genes code for the major histocompatibility complex, the cell-surface proteins that regulate our immune systems.

The second project will expand OMF’s current big-data genome study to patients of varying severities and their families, performing clinical and molecular tests that could provide insight into genetic factors and molecular biomarkers for ME. Right now, it has data from 20 ME patients. The third project will work toward a diagnostic that can distinguish ME blood samples from healthy ones using new technology developed at Stanford. The technology also will be used to test Food and Drug Administration–approved drugs considered for clinical trials on ME patients.

If you ask Lizzie what she would do if she weren’t sick, she says any number of things, starting with returning to school. Here, she and her father, Don Mooney, share a laugh while studying a map on her bedroom wall. LILY WILLIAMS

“We need researchers to share their results openly and collaborate and look at ME / CFS through many body systems, genetics, infectious disease, immunology, metabolomics, microbiome and more,” Tannenbaum said. “The urgent need is not only research but awareness in the medical community and teaching new doctors in medical schools to be able to identify and acknowledge this.”


Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669